[Postmarketing surveillance on Benazepril].
OBJECTIVE
To investigate the long-term effect, safety and tolerability of benazepril in general hypertensive patients.


METHODS
We conducted a three-year community-based postmarketing surveillance on benazepril among 1831 essential hypertensive patients (age range from 35 to 88 years) in Shanghai.


RESULTS
74.3% of patients persisted in medication taking and were with optimal compliance in a 3-year-follow-up program. Among those taking medication as prescribed after 3 years, 75.7% of them attained systolic blood pressure (SBP) target level of 140 mm Hg (1 mm Hg = 0.133 kPa), 87.4% attained diastolic blood pressure (DBP) target level of 90 mm Hg, and 71.5% attained total target level of 140/90 mm Hg. The reductions were approaching 15 mm Hg for SBP, 10 mm Hg for DBP, and 5 mm Hg for pulse pressure (PP) during the 3 year period. No serious adverse drug reactions (ADRs) were detected during the 3 years follow-up. Cough was the most common ADR. The cumulative incidence of benazepril related cough was 23.6% in women, significant higher than in men (18.8%).


CONCLUSIONS
Benazepril was safe and tolerable when applied in hypertensive patients.
Lu
Jun
J
Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing 100083, China.
Li
Li-ming
LM
Cao
Wei-hua
WH
Zhan
Si-yan
SY
Hu
Yong-hua
YH
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001552:Benzazepines / Q000009:adverse effects / Q000627:therapeutic use*; D002681:China / Q000453:epidemiology; D003371:Cough / Q000139:chemically induced / Q000453:epidemiology; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D011358:Product Surveillance, Postmarketing
D000959:Antihypertensive Agents; D001552:Benzazepines; C044946:benazepril